A covered call identified by MarketIntelligececenter.com's patented algorithm on Acorda Therapeutics (ACOR) could yield about 15.26% (23.73% annualized, for comparison purposes only) in 235 days. Pair a long position in the stock with …
SmarTrend identified an Uptrend for Acorda Therapeut (NASDAQ:ACOR) on December 27th, 2017 at $22.40. In approximately 3 months, Acorda Therapeut has returned 14.29% as of today's recent price of $25.60. In the past 52 …
Acorda ACOR, +0.00% stock was slammed in Wednesday trade, declining 39.7%. The company will continue to study the drug, tozadenant, in late-stage clinical trials, though it is now monitoring patients’ blood cell count more frequently and …
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has …
It has been about a month since the last earnings report for Acorda Therapeutics, Inc. ACOR. Shares have lost about 8.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's …
Yahoo!10mon
Acorda Therapeutics Inc. (ACOR) announced Wednesday morning that it has halted ... Shares finished with a loss of 11.20 at $17.00 on the highest volume of the year. The stock tumbled to a 5-month low.
Acorda Therapeutics, Inc. ACOR reported adjusted earnings of 43 cents per share ... View photos Including the impact of stock-based compensation expenses as well as other non-recurring items, the company incurred a loss of 55 cents per …